Drug class · Oncology & immunology
Kinase inhibitors
Small-molecule drugs that inhibit one or more protein kinases. Most are oral products dispensed by pharmacies.
Most-listed names in this class
Ranked by the number of FDA listings, which reflects labelers and package variety — not sales or prescribing.
FDA-listed products
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Alecensaalectinib hydrochloride | Alectinib hydrochloride 150 mg/1 | CapsuleOral | Genentech, Inc. | 50242-130 |
| Afatinib | Afatinib dimaleate 30 mg/1 | Tablet, Film coatedOral | Camber Pharmaceuticals, Inc. | 31722-782 |
| Afatinib | Afatinib dimaleate 20 mg/1 | Tablet, Film coatedOral | Camber Pharmaceuticals, Inc. | 31722-781 |
| Afatinib | Afatinib dimaleate 40 mg/1 | Tablet, Film coatedOral | Camber Pharmaceuticals, Inc. | 31722-783 |
| Afinitoreverolimus | Everolimus 7.5 mg/1 | TabletOral | Novartis Pharmaceuticals Corporation | 0078-0620 |
| Afinitoreverolimus | Everolimus 5 mg/1 | TabletOral | Novartis Pharmaceuticals Corporation | 0078-0566 |
| Afinitoreverolimus | Everolimus 10 mg/1 | TabletOral | Novartis Pharmaceuticals Corporation | 0078-0567 |
| Afinitoreverolimus | Everolimus 2.5 mg/1 | TabletOral | Novartis Pharmaceuticals Corporation | 0078-0594 |
| Afinitor Disperzeverolimus | Everolimus 2 mg/1 | Tablet, For suspensionOral | Novartis Pharmaceuticals Corporation | 0078-0626 |
| Afinitor Disperzeverolimus | Everolimus 3 mg/1 | Tablet, For suspensionOral | Novartis Pharmaceuticals Corporation | 0078-0627 |
| Afinitor Disperzeverolimus | Everolimus 5 mg/1 | Tablet, For suspensionOral | Novartis Pharmaceuticals Corporation | 0078-0628 |
| Alunbrigbrigatinib | Brigatinib 90 mg/1 | Tablet, Film coatedOral | Takeda Pharmaceuticals America, Inc. | 63020-090 |
| Alunbrigbrigatinib | Brigatinib 30 mg/1 | Tablet, Film coatedOral | Takeda Pharmaceuticals America, Inc. | 63020-113 |
| Alunbrigbrigatinib | Brigatinib 180 mg/1 | Tablet, Film coatedOral | Takeda Pharmaceuticals America, Inc. | 63020-180 |
| Anzupgodelgocitinib | Delgocitinib 20 mg/g | CreamTopical | LEO Pharma, Inc | 50222-280 |
| Augtyrorepotrectinib | Repotrectinib 40 mg/1 | CapsuleOral | E.R. Squibb & Sons, L.L.C. | 0003-4040 |
| Augtyrorepotrectinib | Repotrectinib 160 mg/1 | CapsuleOral | E.R. Squibb & Sons, L.L.C. | 0003-4160 |
| Ayvakitavapritinib | Avapritinib 25 mg/1 | Tablet, Film coatedOral | Blueprint Medicines Corporation | 72064-125 |
| Ayvakitavapritinib | Avapritinib 100 mg/1 | Tablet, Film coatedOral | Blueprint Medicines Corporation | 72064-110 |
| Ayvakitavapritinib | Avapritinib 200 mg/1 | Tablet, Film coatedOral | Blueprint Medicines Corporation | 72064-120 |
| Ayvakitavapritinib | Avapritinib 300 mg/1 | Tablet, Film coatedOral | Blueprint Medicines Corporation | 72064-130 |
| Ayvakitavapritinib | Avapritinib 50 mg/1 | Tablet, Film coatedOral | Blueprint Medicines Corporation | 72064-150 |
| Balversaerdafitinib | Erdafitinib 4 mg/1 | Tablet, Film coatedOral | Janssen Products LP | 59676-040 |
| Balversaerdafitinib | Erdafitinib 3 mg/1 | Tablet, Film coatedOral | Janssen Products LP | 59676-030 |
| Balversaerdafitinib | Erdafitinib 5 mg/1 | Tablet, Film coatedOral | Janssen Products LP | 59676-050 |